NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 12.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 125,705 shares of the medical research company’s stock after acquiring an additional 14,148 shares during the quarter. Texas Permanent School Fund Corp owned 0.10% of NeoGenomics worth $1,742,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Blue Trust Inc. increased its position in NeoGenomics by 107.2% during the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock worth $32,000 after buying an additional 1,206 shares during the last quarter. Burkett Financial Services LLC bought a new position in NeoGenomics in the fourth quarter worth $46,000. Quadrant Capital Group LLC lifted its position in shares of NeoGenomics by 22.0% during the 4th quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock worth $79,000 after buying an additional 883 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of NeoGenomics by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 1,791 shares in the last quarter. Finally, Banque Cantonale Vaudoise increased its holdings in NeoGenomics by 10.2% during the 2nd quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 1,633 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on NEO. Stephens reiterated an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Benchmark reissued a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.89.

NeoGenomics Stock Performance

Shares of NEO stock opened at $16.16 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.93 and a current ratio of 2.01. NeoGenomics, Inc. has a fifty-two week low of $11.03 and a fifty-two week high of $21.22. The stock has a 50 day moving average price of $15.98 and a two-hundred day moving average price of $14.94. The company has a market capitalization of $2.06 billion, a P/E ratio of -24.48 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $164.50 million during the quarter, compared to analyst estimates of $161.82 million. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. During the same quarter in the prior year, the company earned ($0.09) EPS. The business’s revenue was up 12.0% compared to the same quarter last year. Analysts expect that NeoGenomics, Inc. will post -0.22 earnings per share for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.